US 10028911
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
granted A61KA61K31/198A61K31/25
Quick answer
US patent 10028911 (Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent) held by Pacira Pharmaceuticals, Inc. expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Pacira Pharmaceuticals, Inc.
- Grant date
- Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/198, A61K31/25, A61K31/519, A61K31/575